



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Abciximab

Cat. No.:	HY-P9934
CAS No.:	143653-53-6
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors ^[1] .	
In Vitro	Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet $\alpha_{IIb}\beta_3$ integrin ^[2] . Abciximab appears to have similar affinity for the $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ integrins and redistributes between them ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Wistar rats weighing 200-250 g, balloon angioplasty model ^[2]
	Dosage:	0.25 mg/kg/day
	Administration:	Intravenous injection, 28 days
	Result:	Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB ₂ concentration.

REFERENCES

- [1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. *Drugs*. 2003;63(11):1121-63.
- [2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. *Thromb Res*. 2001 Feb 1;101(3):127-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA